

Press release
Paris, 2011 the 29th of march

French pathogens discovery biotechnology start –up, PathoQuest SAS, raises 2M€ with Kurma BioFund in its first round of financing

Founded in September 2010 by Professor Marc Eloit and Luc Boblet (PhD), PathoQuest SAS completed, on March 11th 2011, its first round of financing securing 2 M€ with the Kurma BioFund. A spin-off from the Pasteur Institute and the Ecole Nationale Vétérinaire d'Alfort (ENVA), PathoQuest has developed a proprietary expertise in metagenomics and pathogens identification by "Binning" or "De novo assembling" of high-throughput generated sequences.

By discovering the etiology of major pathologies, in the field of infectious diseases and oncology, PathoQuest is committed to providing valuable new targets for diagnosis and vaccines to majors companies.

Professor Marc Eloit, President and Chief Scientific Officer: "Thanks to this agreement, I am glad to be in a position to enlarge our core expertise, combining knowledge in infectiology and state of the art bioinformatics, for improved diagnosis and therapeutics of patients".

PathoQuest is developing a dual-business model combining solely-owned R&D programs and a broad range of partnerships in discovery and services in pathogen identification.

Luc Boblet, PathoQuest CEO's: "I am particularly proud of this achievement and of the strong support of the Pasteur Institute, ENVA and the Kurma BioFund in facilitating the inception of PathoQuest".

Thierry Laugel, Managing Partner at Kurma BioFund: "PathoQuests' funding is the result of a long development process with the founders, in close collaboration with the Pasteur Institute and the Kurma BioFund. It highlights Kurma's knowledge and the success it has had in technology transfer projects, as PathoQuest is the 5th biotech project in the last year in the context of partnerships with academic institutions of excellence".

Professor Alice Dautry, Managing Director of the Pasteur Institute: "We are delighted with the success of this first closing which will enable us to partake in the development of PathoQuest's technology. PathoQuest's expertise is very promising, offering a wide range of highly valuable applications."

Professor Jean-Paul Mialot, Managing Director of ENVA: " I must thank the PathoQuest founders who convinced us to invest in this innovative project which perfectly fits with ENVA's strategic axis. Their knowledge and determination will be the best guarantee to ensure its success".

About PathoQuest

A spin-off from the Pasteur Institute and l'Ecole Nationale Vétérinaire d'Alfort (ENVA), PathoQuest is a biotechnology start-up company dedicated to identifying pathogens by means of High Throughput Sequencing (HTS). PathoQuest's extensive range of R&D programs in the fields of infectious diseases and oncology - both in-house and in collaboration with academic/industrial partners, permits PathoQuest to discover the etiology of major pathologies. PathoQuest is committed to providing diagnosis and vaccine pharmaceutical companies with valuable new targets. PathoQuest ultimately aims to be a pioneer in HTS-based medical diagnosis.

Contact: luc.boblet@pathoquest.com Tel +33 (0)1 40 61 39 16 www.pathoquest.com

About Kurma Life Sciences Partners

Kurma Biofund is a venture capital fund managed by Paris based Kurma Life Sciences Partners (KLS Partners). Founded in July 2009, Kurma manages in excess of 135M€. KLS Partners is supported by two long-term investors (Natixis, part of Group BPCE the second largest French bank, and state-owned Caisse des Dépôts et Consignations – CDC). Kurma actively invests in all stages of the biotech value chain, from technology transfer through to more established companies.

Contact : thierry.laugel@kurmabiofund.com Tel +33 (0)1 58 19 44 07 www.kurmabiofund.com

About Institut Pasteur

Renowned for its public health services and its biomedical research center, the Pasteur Institute, founded by Louis Pasteur, is a private non-profit foundation located in Paris. While it employs almost 2600 individuals, whose mission is to contribute to the prevention and the fight against diseases worldwide through research, education, and public health activities, the major focus of its work lies in investigations in the field of infectious diseases, genetics, neurodegenerative pathologies, and oncology. The Pasteur Institute is a member of a global network comprising 32 research institutes. Since its inception, 10 scientists have been awarded the Nobel Prize for Medicine.

www.pasteur.fr

About Ecole Nationale Vétérinaire d'Alfort

Founded in its current location in 1765, the Ecole Nationale Vétérinaire d'Alfort (ENVA) is a public research center excelling in the field of infectious diseases and in public health. ENVA regularly collaborates with physicians, veterinarians and scientists from the Pasteur Institute. As the oldest veterinary school in the world, ENVA brings together 400 individuals including 140 scientists, in addition to its 700 students. ENVA also collaborates with leading research organizations including ANSES, INRA, INSERM and prestigious universities. With 4 research units (out of 10 in total onsite) dedicated to infectious diseases and epidemiology, ENVA offers additional key expertise in animal models and clinical investigations in its 35000 plus yearly procedures on domestic animals.

www.vet-alfort.fr